alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.7



 Exhibit 10.7 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

FIRST AMENDMENT TO LICENSE AGREEMENT 

This First Amendment (hereinafter called the “First Amendment”) to the License Agreement, as defined below, entered into as of the 17 day of March,
2014 (hereinafter called “First Amendment Execution Date”) is by and between AstraZeneca AB, a Swedish corporation having its principal place of business at Västra Mälarehamnen 9, Södertälje, SE-151 85, Sweden
(“AstraZeneca”), and Flexion Therapeutics, Inc., a corporation organized under the laws of the State of Delaware and having a principal place of business at 10 Mall Road Suite 301, Burlington Massachusetts 01803 (“Flexion”).
AstraZeneca and Flexion are hereinafter referred to each as a “Party” and collectively as the “Parties.” 
 WHEREAS,
AstraZeneca and Flexion Therapeutics entered into that certain license agreement effective September 13, 2010 (“License Agreement”) under which Flexion Therapeutics AG obtained from AstraZeneca and AstraZeneca granted to Flexion
Therapeutics AG certain licenses to develop and commercialize the Compounds and Licensed Products. 
 WHEREAS, the Parties desire to amend
the License Agreement to amend certain defined terms related to Flexion’s sub-licensing rights. 
 NOW, THEREFORE, in consideration of
the mutual provisions and covenants contained herein, the Parties hereby agree as follows: 
 1. The terms in the License Agreement shall have the
same meanings in this First Amendment, and capitalized terms used herein but not otherwise defined have the meanings assigned to them in the License Agreement. 

2. Section 1.80 of the License Agreement is hereby deleted in its entirety and is replaced with the following: 

“‘Proof of Concept’ means with regard to Compound or a Licensed Product, clinical trial results which provide sufficient
evidence of efficacy and safety in approximately [...***...]. 
 3. Except as expressly amended in this First Amendment, the License Agreement shall
continue in full force and effect in accordance with the provisions thereof prior to the effectiveness of this First Amendment. 
 4. This First
Amendment may be executed by one or more of the Parties to this First Amendment on any number of separate counterparts (including by facsimile transmission or other electronic transmission), and all of said counterparts taken together shall be
deemed to constitute one and the same instrument. 
 ***Confidential Treatment Requested 







 IN WITNESS WHEREOF, the Parties hereto have executed and delivered this First Amendment by their
duly authorized representatives as of the First Amendment Execution Date. 
  

									
	ASTRAZENECA AB	 		 	FLEXION THERAPEUTICS, INC.
			
	 /s/ Christoph Pittius
	 		 	 /s/ Michael Clayman

	Signature	 		 	Signature
					
	Name:	 	 Christoph Pittius Ph.D.
	 		 	Name:	 	 Michael Clayman

	Title:	 	 VP, Head of Transactions
	 		 	Title:	 	 CEO

					
	Date:	 	March 19, 2014	 		 	Date:	 	March 17, 2014
<TABLE>
                          HEALTHY PLANET PRODUCTS, INC.

                        COMPUTATION OF EARNINGS PER SHARE
                                   EXHIBIT 11


<CAPTION>


                                                  Three Months Ended  Three Months Ended

                                                      March 31, 1997   March 31, 1996
                                                      --------------   --------------

Primary earnings per share
<S>                                                    <C>              <C>       
         Net (loss) income                             $  (129,654)     $   82,366
         Dividends paid on preferred stock                    --              --
         Cumulative dividends on preferred stock              --              --
                                                       -----------      ----------

(Loss)/Income applicable to common stock               $  (129,654)     $   82,366
                                                       ===========      ==========

Shares
         Weighed average number of common
             shares outstanding                          1,827,362       1,812,362
         Add dilutive effect of conversion of
             preferred stock and outstanding
             options and warrants, as determined
             by the application of the treasury
             stock method                                     --           242,804
                                                       -----------      ----------

                                                         1,827,362       2,055,166
                                                       ===========      ==========

Primary earnings per share                             $      (.07)     $      .04
                                                       ===========      ==========
</TABLE>

                                 Page 12 of 13

<PAGE>

                           PART II. OTHER INFORMATION




Item 6.  Exhibits and Reports on Form 8-K

         a.     Exhibits

                None

         b.     Reports on Form 8-K

         During the quarter ended March 31, 1997,  there were no reports on Form
8-K filed by the Registrant.



                                   SIGNATURES

  In  accordance  with the  requirements  of the  Securities  Exchange  Act, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                           HEALTHY PLANET PRODUCTS, INC.
                                                   (Registrant)


DATED: May 14, 1997
                                    by:       s/ Bruce A. Wilson
                                       -----------------------------------------
                                              Bruce A. Wilson
                                              President,  Chief Executive, Chief
                                              Operating   and  Chief   Financial
                                              Officer.


                                  Page 13 of 13
EXHIBIT 31.b

CERTIFICATION PURSUANT TO18 U.S.C. 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Black Gardenia Corp. (the "Company")on Form 10-KSB for the period ended December 31, 2004, as filed with theSecurities and Exchange Commission on the date hereof (the "Report"), I, Amy Ng,Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

- The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and   
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.

 

| Date: February 28, 2006. | /s/ Amy Ng

_______________________   Amy Ng   Acting Chief Financial Officer |
|--------------------------|-------------------------------------------------------------------------------|
[Federal Register Volume 75, Number 165 (Thursday, August 26, 2010)]
[Notices]
[Page 52538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Research Resources; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Research Resources 
Special Emphasis Panel SEPA.
    Date: October 18-19, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda Downtown, 7335 Wisconsin Avenue, 
Bethesda, MD 20814.
    Contact Person: Sheri A Hild, PhD, Scientific Review Officer, 
National Institutes of Health, National Center for Research 
Resources, Office of Review, 6701 Democracy Blvd., Rm 1082, 
Bethesda, MD 20892. 301-435-0811. <a href="/cdn-cgi/l/email-protection#5c343530382f3d1c313d353072323534723b332a"><span class="__cf_email__" data-cfemail="771f1e1b130416371a161e1b59191e1f59101801">[email protected]</span></a>.

    Name of Committee: National Center for Research Resources 
Special Emphasis Panel, COBRE III Meeting.
    Date: October 19-20, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Rockville, 1750 Rockville Pike, Plaza I, 
Rockville, MD 20852.
    Contact Person: Steven Birken, PhD, Scientific Revew Officer, 
Office of Review, National Center for Research Resources, National 
Institutes of Health, 6701 Democracy Blvd., Dem. 1, Room 1078, MSC 
4874, Bethesda, MD 20892-4874. 301-435-0815. <a href="/cdn-cgi/l/email-protection#24464d564f414a576449454d480a4a4d4c0a434b52"><span class="__cf_email__" data-cfemail="fa989388919f9489ba979b9396d4949392d49d958c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical 
Technology; 93.389, Research Infrastructure, 93.306, 93.333; 93.702, 
ARRA Related Construction Awards., National Institutes of Health, 
HHS)

    Dated: August 20, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-21280 Filed 8-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 12
 CAPSTEAD MORTGAGE CORPORATION
COMPUTATION OF RATIO OF INCOME FROM CONTINUING OPERATIONS (BEFORE  FIXED CHARGES) TO COMBINED FIXED
CHARGES AND PREFERRED STOCK  DIVIDENDS
(In thousands, except ratios)
(Unaudited)
  Three MonthsEnded
    
    
    Year Ended December 31,March 31, 2008
    
    
    2007
    
    
    2006
    
    
    2005
    
    
    2004
    
    
    2003Fixed charges
    
    $
    71,493
    
    
    $
    275,648
    
    
    $
    235,521
    
    
    $
    106,909
    
    
    $
    44,939
    
    
    $
    58,924Preferred stock dividends
    
    
    5,064
    
    
    
    20,256
    
    
    
    20,256
    
    
    
    20,256
    
    
    
    20,259
    
    
    
    20,273Combined fixed charges and
preferred stock dividends
    
    $
    76,557
    
    
    $
    295,904
    
    
    $
    255,777
    
    
    $
    127,165
    
    
    $
    65,198
    
    
    $
    79,197Fixed charges
    
    $
    71,493
    
    
    $
    275,648
    
    
    $
    235,521
    
    
    $
    106,909
    
    
    $
    44,939
    
    
    $
    58,924Income from continuing
operations
    
    
    30,147
    
    
    
    24,713
    
    
    
    3,843
    
    
    
    17,195
    
    
    
    39,869
    
    
    
    58,666$
    101,640
    
    
    $
    300,361
    
    
    $
    239,364
    
    
    $
    124,104
    
    
    $
    84,808
    
    
    $
    117,590Ratio of income from continuing
operations (before fixed
charges) to combined fixed
charges and preferred
stock dividends
    
    
    1.33:1
    
    
    
    1.02:1
    
    
    
    
    
    
    
    
    
    
    
    1.30:1
    
    
    
    1.48:1Deficiency of income from
continuing operations (before
fixed charges) to combined fixed
charges and preferred stock
dividends
    
    
    
    
    
    
    
    
    
    $
    16,413
    
    
    $
    3,061
| Skip to Content*Release Date: June 9, 2011*Release dates | Announcements | Coded tables | Historical dataCurrent release | Screen reader | PDF (450 KB) | Data Download Program (DDP)**Growth of Domestic Nonfinancial Debt** |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
Exhibit 32.2

CERTIFICATION FURNISHED PURSUANT TO  18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Techwell, Inc. (the "Company") for the annual period ended December 31, 2007
as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark Voll, Vice President, Finance and Administration and Chief Financial Officer of the Company, hereby
certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:



| |  | /s/MARK VOLLMark Voll Vice President of Finance and Administration and
Chief Financial OfficerMarch 12, 2008
| |  | ------------------------------------------------------------------------------------------------------------

---



QuickLinks
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF SEROLOGICALS CORPORATION
FOR THE QUARTER ENDED SEPTEMBER 27, 1998, AS SET FORTH IN ITS FORM 10Q
FOR SUCH QUARTER AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-27-1998
<PERIOD-START>                             DEC-29-1997
<PERIOD-END>                               SEP-27-1998
<CASH>                                          32,713
<SECURITIES>                                         0
<RECEIVABLES>                                   18,996
<ALLOWANCES>                                         0
<INVENTORY>                                     12,953
<CURRENT-ASSETS>                                66,897
<PP&E>                                          25,174
<DEPRECIATION>                                   9,404
<TOTAL-ASSETS>                                 141,416
<CURRENT-LIABILITIES>                           14,101
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           245
<OTHER-SE>                                     123,756
<TOTAL-LIABILITY-AND-EQUITY>                   141,416
<SALES>                                         91,506
<TOTAL-REVENUES>                                91,506
<CGS>                                           59,953
<TOTAL-COSTS>                                   59,953
<OTHER-EXPENSES>                                 1,995
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (632)
<INCOME-PRETAX>                                 18,663
<INCOME-TAX>                                     6,644
<INCOME-CONTINUING>                             12,019
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    12,019
<EPS-PRIMARY>                                      .50
<EPS-DILUTED>                                      .47
        

</TABLE>
<PAGE>

                                                                    Exhibit 32.1


                                  CERTIFICATION

            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                    (SUBSECTIONS (a) AND (b) OF SECTION 1350,
                   CHAPTER 63 OF TITLE 18, UNITED STATES CODE)



Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of title 18, United States Code), the
undersigned officer of AMERICAN TECHNICAL CERAMICS CORP., a Delaware corporation
(the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the period ended March 31, 2004 (the "Form
10-Q") of the Company fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, and the information contained in
the Form 10-Q fairly presents, in all material respects, the financial condition
and results of operations of the Company.




          Dated: May 13, 2004                       /S/ VICTOR INSETTA
                                                    -------------------------
                                                    Chief Executive Officer



A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
----

**Exhibit 23.1**

Board of DirectorsU.S Geothermal, Inc.Boise, ID

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the use of our audit report dated June 10, 2009, except Note 2 which is dated October 22, 2009, on the consolidated financial statements of U.S. Geothermal, Inc. for the years ended March 31, 2009, 2008 and 2007, as filed with the Form 10-K/A and by reference to the outstanding Forms S-3 (333-158355), S-3A (333-151858) and S-8 (333-141262) as previously filed.

/s/ BehlerMick PS                                       BehlerMick PS
Exhibit 31 

CERTIFICATION 

I, Richard Smitten, CEO and CFO,certify that: 

1.              I have reviewed this annual report on Form 10-KSB of Stock Market Solutions,          Inc.; 

2.              Based on my knowledge, this quarterly report does not contain any untrue          statement of a material fact or omit to state a material fact necessary to make          the statements made, in light of the circumstances under which such statements          were made, not misleading with respect to the period covered by this quarterly          report; 

3.              Based on my knowledge, the financial statements, and other financial information          included in this quarterly report, fairly present in all material respects the          financial condition, results of operations and cash flows of the registrant as          of, and for, the periods presented in this quarterly report; 

4.              I am responsible for establishing and maintaining disclosure controls and          procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the          registrant and we have: 

    a)                 designed such disclosure controls and procedures, or caused such disclosure          controls and procedures to be designed under our supervision, to ensure that          material information relating to the registrant is made known to us by others          within the Corporation, particularly during the period in which this quarterly          report is being prepared; 

    b)                 evaluated the effectiveness of the registrant’s disclosure controls and          procedures and presented in this report our conclusions about the effectiveness          of the disclosure controls and procedures, as of the end of the period covered          by this report based on such evaluation; and 

    c)                 disclosed in this report any change in the registrant’s internal control          over financial reporting that occurred during the registrant’s most recent          fiscal quarter that has materially affected, or is reasonably likely to          materially affect, the registrant’s internal control over financial          reporting; and 

5.              I have disclosed, based on my most recent evaluation of internal control over          financial reporting, to the registrant’s auditors and the audit committee          of registrant’s board of directors (or persons performing the equivalent          function): 

    a)                 all significant deficiencies and material weaknesses in the design or operation          of internal control over financial reporting which are reasonably likely to          adversely affect the registrant’s ability to record, process, summarize and          report financial information; and 

    b)                 any fraud, whether or not material, that involves management or other employees          who have a significant role in the registrant’s internal control over          financial reporting. 

Date: March 18, 2004
**Exhibit 32(b)**

 

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with theQuarterly Report of Hickory Tech Corporation (HickoryTech) on Form 10-Q for theperiod ending June 30, 2004 as filed with the Securities and ExchangeCommission on the date hereof (the Report), I, David A. Christensen, ChiefFinancial Officer of HickoryTech, certify, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1)                                  TheReport fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2)                                  Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of HickoryTech.

 

 
| /s/ David A.  Christensen |   |
|---------------------------|--------|
| David A.  Christensen     |
| Chief  Financial Officer  |
| August 4,  2004           |

 

1

----
EXHIBIT 1


   [LOGO]                    [ ] MetroPark               [ ] Phone: 732 906-3200
                                 99 Wood Avenue South
                                 Iselin, New Jersey 08830-0471



July 13, 1998


Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549


Gentlemen:

We have read Item 4 of Form 8-K dated July 13,  1998,  of FOHP,  Inc. and are in
agreement  with  the  statements  contained  in  the  first,  second  and  third
paragraphs  on page 2 therein.  We have no basis to agree or disagree with other
statements of the registrant contained therein.



                                                 /s/Ernst & Young LLP
                                                 -------------------------------
                                                 Ernst & Young LLP





       Ernst & Young LLP is a member of Ernst & Young International, Ltd.